Viridian Therapeutics Announced Phase 1 Results For VRDN-008; Demonstrated Deep And Sustained IGG Reduction Through 8 Weeks After Subcutaneous Dosing, With 74% Reduction At Peak
Benzinga Newsdesk 6 hours ago
News
VRDN-008 demonstrated an extended half-life of 15–18 days, up to 6x longer than the first-generation Fc fragments -- VRDN-008 demonstrated a safety profile that spared albumin and LDL and was generally well tolerated --
VRDN-008 demonstrated an extended half-life of 15–18 days, up to 6x longer than the first-generation Fc fragments -
- VRDN-008 demonstrated a safety profile that spared albumin and LDL and was generally well tolerated -
- Viridian plans to initiate at least one pivotal clinical trial in 2027, starting with myasthenia gravis (MG) in mid-2027, pending regulatory feedback -
- Planned MG placebo-controlled multi-arm trial design with Q4W and Q8W dosing supports direct-to-registrational path -
- With the potential to deliver transformative patient impact across autoantibody-mediated autoimmune diseases, Viridian plans to develop VRDN-008 broadly in multiple of these autoimmune diseases -
- Viridian to host investor conference call and webcast today at 8:00 am ET